Brunswick Group, the strategic advisory firm focused on critical issues, today announced the appointment of two Partners in Asia. Xi Qing joins as a Partner in Shanghai with a focus on the healthcare and life sciences sector. Pru Bennett is now a Partner with a focus on corporate governance, having been a Senior Advisor of the firm since May 2019.
Qing most recently worked for Pfizer as Vice President of Government Affairs, Market Access and Communications, overseeing the full scope of corporate affairs activities for Pfizer’s established brands business in China.
Before joining Brunswick as a Senior Advisor, Pru gained more than 25 years’ experience working in corporate governance. Prior to Brunswick, she was Managing Director at BlackRock and Head of BlackRock’s Investment Stewardship team for the Asia Pacific region.
Neal Wolin, Chief Executive Officer, said: “Asia continues to be a critical region for Brunswick. Qing and Pru add significant weight to our capabilities in healthcare and life sciences and corporate governance, respectively, and will put Brunswick in an even stronger position to capitalize on growth opportunities in the region.”
Lisa Foley, Asia Managing Partner, said: “We are delighted to welcome Qing and Pru. Our clients will benefit greatly from their wealth of knowledge and senior counsel, as they navigate the increasingly complex environment across Asia.”
On joining the firm, Xi Qing said: “I am excited to join the growing team at Brunswick in China and look forward to strengthening the firm’s healthcare and life sciences capabilities in Asia.”
Pru Bennett said: “I am thrilled to deepen my contribution to Brunswick by becoming a Partner. I look forward to continuing to work closely with colleagues across Asia to advise the senior management teams and boards of clients on a range of governance issues.”
About Xi Qing
Qing has more than 20 years of experience in communications, market access, government affairs, crisis management and corporate social responsibility at multinational companies. He spent the last 16 years at Pfizer China, where he held several senior roles, most recently as Vice President of Government Affairs, Market Access and Communications. In this role, he led a team of 80 people to support Pfizer’s business and operations in China, overseeing central and local government affairs, corporate communications, brand communications, and pricing and market access. Prior to Pfizer, Qing worked at Intel supporting communications across China.
Qing also served as Co-Chairman of the Communication Working Group of RDPAC, the R&D-based Pharmaceutical Association Committee.
Qing holds an executive MBA from China European International Business School and a Bachelor of Material Science & Engineering from Shanghai Jiao Tong University.
About Pru Bennett
Pru Bennett joined Brunswick Group following a career at BlackRock where she was a Managing Director and Head of Investment Stewardship for the APAC region. At BlackRock Pru led a team responsible for engagement and proxy voting activities in relation to the companies in which BlackRock invests on behalf of clients.
Pru is an active participant in the public debate on corporate governance, stewardship and responsible investment and as such regularly speaks and writes on the importance of these issues for company performance and investment decisions. In 2018 Pru received the Asia Industry Leadership Award from 100 Women in Finance. In 2013, Pru was named as one of Australia’s top 10 Women of Influence in Corporate Governance.
Pru is Chairman of the National Foundation for Australia China Relations, a director of Global Compact Network Australia and a member of a number of industry and regulatory bodies including Public Shareholder Group of Hong Kong’s Securities and Futures Commission, the Monetary Authority of Singapore's Corporate Governance Advisory Committee, a council member of the Asian Corporate Governance Association, director of the International Integrated Reporting Council and a member of the Deakin University Integrated Reporting Centre Advisory Board.
Tel: +852 9783-1700
Email: [email protected]